



Published in final edited form as:

*Nat Commun.* ; 2: 390. doi:10.1038/ncomms1381.

## The Wnt3a/ $\beta$ -catenin target gene *Mesogenin1* controls the segmentation clock by activating a Notch signaling program

Ravindra B. Chalamalasetty<sup>1,\*</sup>, William C. Dunty Jr.<sup>1,\*</sup>, Kristin K. Biris<sup>1</sup>, Rieko Ajima<sup>1</sup>, Michelina Iacovino<sup>2</sup>, Arica Beisaw<sup>1</sup>, Lionel Feigenbaum<sup>3</sup>, Deborah L. Chapman<sup>4</sup>, Jeong Kyo Yoon<sup>5</sup>, Michael Kyba<sup>2</sup>, and Terry P. Yamaguchi<sup>1,#</sup>

<sup>1</sup>Cancer and Developmental Biology Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, NIH, Frederick, MD 21702, USA

<sup>2</sup>Lillehei Heart Institute and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA

<sup>3</sup>Laboratory Animal Sciences Program, National Cancer Institute-Frederick Frederick, MD 21702, USA

<sup>4</sup>Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA

<sup>5</sup>Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, ME 04074, USA

### Summary

Segmentation is an organizing principle of body plans. The segmentation clock, a molecular oscillator best illustrated by the cyclic expression of Notch signaling genes, controls the periodic cleavage of somites from unsegmented presomitic mesoderm (PSM) during vertebrate segmentation. Wnt3a controls the spatiotemporal expression of cyclic Notch genes, however the underlying mechanisms remain obscure. Transcriptional profiling of *Wnt3a*<sup>-/-</sup> embryos led to the identification of the bHLH transcription factor, *Mesogenin1* (*Msgn1*), as a direct target gene of Wnt3a. To identify *Msgn1* targets, we performed genome-wide studies of *Msgn1* activity in embryonic stem cells. Here we show that *Msgn1* is a major transcriptional activator of a Notch signaling program, synergizing with Notch to trigger clock gene expression. *Msgn1* also indirectly regulates cyclic genes in the Fgf and Wnt pathways. Thus, *Msgn1* is a central component of a transcriptional cascade that translates a spatial Wnt3a gradient into a temporal pattern of clock gene expression.

### Introduction

Somites are blocks of paraxial mesoderm that bud from the anterior PSM every 2 hours in the mouse embryo, and ultimately give rise to the musculoskeletal system. The timing of somitogenesis is controlled by a network of oscillating genes in the Notch, Wnt and Fgf signaling pathways<sup>1</sup>. Notch target genes such as *Lunatic fringe* (*Lfng*) are amongst the first cyclic genes to be characterized<sup>2</sup>. *Lfng* is first expressed in the posterior PSM and sweeps

#Corresponding author: NCI-Frederick, 1050 Boyles St., Bldg. 539, Rm. 218, Frederick, MD 21702, Phone: 301-846-1732, FAX: 301-846-7117, yamagute@mail.nih.gov.

\*co-first authors

**Author Contributions:** R.B.C., W.C.D. and T.P.Y. conceived the experiments. R.B.C., W.C.D. and K.K.B. predominantly performed the work with the help of R.A. and A.B. M.I. and M.K. developed the ESC reagents, L.F. generated transgenic animals, D.L.C. and J.K.Y. provided embryos and mice. T.P.Y. supervised the project and wrote the paper.

**Competing Financial Interests Statement:** The authors declare no competing financial interests.

anteriorly, arresting as a stripe in the anterior PSM, before a repetitive wave of gene expression begins anew<sup>3,4,5</sup>. The oscillation frequency matches the rate of somite formation, leading to the proposal that cyclically-expressed genes constitute a segmentation clock that controls the timing of somitogenesis<sup>6</sup>. The demonstration that the Notch/Fgf pathways oscillate out of phase with the Wnt pathway<sup>1</sup>, and that the loss of activity of any one of the signaling pathways adversely affects oscillatory gene expression in all three pathways<sup>7,8,9,10</sup>, strongly suggests that these signaling pathways interact in a coordinated and reciprocal fashion. Wnt3a, signaling via  $\beta$ -catenin, controls oscillatory gene expression in the Notch pathway since cyclic *Lfng* expression ceases in the absence of either gene<sup>7,8,11</sup>. Although it has been proposed that Wnt signaling does so through the direct activation of the Notch ligand *Dll1*<sup>12</sup>, *Dll1* levels remain surprisingly robust in *Wnt3a* mutants despite the dramatic down regulation of other direct Wnt target genes such as *Axin2*<sup>7,11</sup>. These results suggest that alternative mechanisms might account for the regulation of the Notch pathway and the segmentation clock by Wnt3a.

A posterior-anterior gradient of Wnt3a/ $\beta$ -catenin and Fgf activity across the PSM plays an important role in translating the rhythmic output of the segmentation clock into a periodic array of somites<sup>13,14</sup>. The Wnt/Fgf gradient positions segment boundaries by establishing a threshold of activity (termed the determination front), below which anterior PSM cells can respond to the segmentation clock by activating the boundary determination genes *Mesoderm posterior 2* (*Mesp2*) and *Ripply2*<sup>8,15,16,17</sup>. Reduced Wnt3a/ $\beta$ -catenin signaling in the anterior PSM is crucial for determination front activity since the overactivation of  $\beta$ -catenin in the anterior PSM maintained the clock and blocked *Mesp2/Ripply2* expression, resulting in a profound elongation of the PSM and delayed somitogenesis<sup>8,18</sup>. Thus, Wnt3a functions in both the clock and the determination front during somitogenesis, however it remains unclear how Wnt3a performs both functions.

Stimulation of the Wnt/ $\beta$ -catenin signaling pathway stabilizes  $\beta$ -catenin, which interacts with members of the Lef/Tcf family of DNA-binding factors to activate the transcription of target genes<sup>19</sup>. We show here that the bHLH transcription factor gene *Msgn1* is a target of the Wnt3a/ $\beta$ -catenin pathway and that the Wnt3a gradient defines the oscillatory field through the induction of *Msgn1*. *Msgn1*, in turn, directly activates the expression of Notch pathway genes, including cyclic genes. Thus, *Msgn1* directly links the Wnt3a signaling gradient to the Notch signaling pathway and the segmentation clock.

## Results

### A Wnt3a gradient defines the *Msgn1* spatial expression domain

Transcriptional profiling of presomite-stage wildtype and *Wnt3a*<sup>-/-</sup> embryos revealed that *Msgn1* is downregulated in *Wnt3a* mutants (Fig. 1a). *Msgn1* was of particular interest since the *Msgn1*<sup>-/-</sup> phenotype, which includes the absence of posterior somites<sup>20</sup>, is similar to the phenotypes observed in *Wnt3a*<sup>-/-</sup> and *Ctnnb1*<sup>fl</sup> ( $\beta$ -catenin) mutants<sup>8,21</sup>. *Msgn1* is an excellent candidate target gene of Wnt3a since it is spatiotemporally coexpressed with *Wnt3a* in the gastrulating (Fig. 1b,c) and segmenting (Fig. 1d) embryo. The *Msgn1* anterior border lies posterior to the stripes of *Mesp2/Ripply2* expression<sup>22</sup> and thus coincides with the position of the determination front. Importantly, the anteroposterior (AP) position of this border in the PSM depends upon *Wnt3a* and *Ctnnb1* activity. *Wnt3a* or *Ctnnb1* loss-of-function (LOF) leads to a loss of *Msgn1* expression (Fig. 1e,f), while the conditional stabilization of  $\beta$ -catenin in the PSM results in a remarkable anterior expansion of *Msgn1* expression (Fig. 1g). To test if Wnt3a can activate *Msgn1* dose-dependently, we treated pluripotent embryonic stem cells (ESC), which retain the potential to form mesoderm, with recombinant Wnt3a in serum-free conditions<sup>23</sup>. Wnt3a treatment led to a potent dose-dependent induction of *Msgn1* mRNA (Fig. 1h). Taken together, the data suggest that the

Wnt3a gradient spatially defines the *Msgn1* expression domain in the PSM, and that the anterior border of *Msgn1* may be an important component of the determination front.

Although our genetic studies, together with in vitro and transgenic analyses of the *Msgn1* promoter (Fig. 2a-d), clearly demonstrate that *Msgn1* is directly controlled by a Wnt3a signaling gradient, *Msgn1* is not highly graded across the PSM at early somitogenesis stages (Fig. 1d) suggesting that additional regulators maintain *Msgn1* in more rostral domains. Previous analysis of the *Msgn1* promoter showed that *Msgn1* is activated by the Tbox transcription factor Tbx6, in addition to Wnt signaling<sup>24</sup>. *Tbx6* is another important regulator of somitogenesis<sup>25</sup> and is thought to be expressed in an identical domain as *Msgn1*<sup>22</sup>. Re-examination of *Tbx6* and *Msgn1* coexpression demonstrates that although similar, *Tbx6* expression exceeds *Msgn1* (Fig. 2e,f), suggesting that Tbx6 is insufficient to define the position of the *Msgn1* anterior border. To determine whether Tbx6 is required for *Msgn1* expression in the anterior PSM, we examined E8.5 *Tbx6*<sup>-/-</sup> embryos by WISH and found that the anterior border of the *Msgn1* domain was indeed shifted posteriorly, and *Msgn1* mRNA was now expressed in a graded fashion in the posterior-most PSM (Fig. 2g,h). Reducing *Wnt3a* dosage on the *Tbx6*<sup>-/-</sup> background led to reductions in *Msgn1* expression below levels observed in *Tbx6*<sup>-/-</sup> embryos (Supplementary Fig. S1), providing genetic evidence that the weak, graded *Msgn1* expression observed in *Tbx6* mutants depends upon Wnt3a. We conclude that Tbx6 maintains *Msgn1* expression in the anterior PSM, functioning together with a Wnt3a gradient to generate an anterior boundary that defines the determination front.

### ***Msgn1* functions in the clock and determination front**

The initial characterization of the segmentation phenotype in *Msgn1*<sup>-/-</sup> embryos was performed on E9.5 embryos, a relatively late stage when mutants already lack posterior somites and PSM and display enlarged tailbuds<sup>20</sup>. The highly abnormal tailbud complicates the interpretation of the segmentation phenotype since the lack of posterior somites could be secondary to an inability of tailbud progenitors to migrate or give rise to PSM fates. Therefore, to address the potential role that *Msgn1* may play in the determination front, we examined *Msgn1*<sup>-/-</sup> mutants for the expression of the segment boundary determination genes *Ripply2* and *Mesp2*, and the posterior somite marker *Uncx4.1*, at E8.5 when mutants are not clearly distinguished from littermates. WISH analysis revealed that all three genes were downregulated, while the primitive streak (PS) marker, *Fgf8*, was unaffected (Fig. 3a-d). The lack of expression of segment boundary determination genes at early somitogenesis stages demonstrates that *Msgn1* is required for determination front activity and suggests that *Msgn1* is a functional effector of the Wnt3a gradient.

*Msgn1* may also play an important role in the segmentation clock since cycling genes in the Notch pathway were shown to be downregulated in *Msgn1* mutants at E9.5<sup>20</sup>. Since this reduced gene expression could arise secondarily, due to the large number of apoptotic cells reported in the E9.5 *Msgn1*<sup>-/-</sup> tailbud<sup>20</sup>, we reinvestigated the expression of cycling genes at the earlier E8.5 stage. We first examined mutants for the expression of cyclic Fgf and Wnt pathway genes, as interactions between all three signaling pathways are necessary for a functional segmentation clock. WISH analysis of *Msgn1*<sup>-/-</sup> embryos, or explanted PSMs processed by the “fix and culture” method<sup>6</sup> to assess the dynamic expression of cycling genes, revealed that the cyclic Wnt target genes *Sp5* (Fig. 4a-f) and *Axin2* (not shown) were upregulated and anteriorly expanded (Fig. 4a,b) but did not oscillate in the *Msgn1*<sup>-/-</sup> PSM (Fig. 4c-f). The oscillating Fgf pathway genes *Sprouty2* (Fig. 4g-l) and *Dusp6* (not shown) were expressed at similar levels in mutants and controls (Fig. 4g,h), but cyclic expression was not observed in *Msgn1* mutants either (Fig. 4i-l). Since all of the Wnt and Fgf target genes examined were expressed, we conclude that *Msgn1* is not required for their activation. However, the static expression patterns in *Msgn1*<sup>-/-</sup> explants after culture suggests that

*Msgn1* is required, directly or indirectly, for the oscillatory expression of cyclic Wnt and Fgf target genes.

Although the cyclic Notch targets *Lfng* and *Hes1* are not expressed in *Msgn1* mutants at E9.5, *Dll1* expression was reportedly reduced but not severely affected<sup>20</sup>, and other cyclic Notch genes such as Notch-regulated ankyrin-repeat protein (*Nrarp*)<sup>26,27</sup>, the Notch transcriptional coactivator Mastermind-like 3 (*Maml3*)<sup>28</sup>, and the periodic transcriptional repressor *Hes7*<sup>29</sup> were not examined. To determine if *Msgn1* plays a central role in the regulation of known Notch clock genes, we examined their expression in *Msgn1*<sup>-/-</sup> embryos at E8.5. WISH revealed that numerous Notch pathway genes including *Dll1*, *Dll3*, *Notch1*, *Hes7*, and *Lfng* were significantly downregulated in the posterior PSM (Fig. 4m,n,s,t,y-d'). The *Lfng* expression pattern closely resembles the expression of *Lfng* in embryos lacking the transcriptional effector of the Notch pathway, RBP-J<sup>30,31</sup>, suggesting that *Msgn1* and RBP-J play equivalent roles in *Lfng* regulation. In contrast, *Nrarp* (Fig. 4e',f') and *Maml3* (not shown) were strongly expressed in the posterior PSM of *Msgn1*<sup>-/-</sup> embryos. Examination of cultured PSM explants demonstrated that the stripes of *Nrarp* expression in the control PSM (Fig. 4o) became broader in the posterior-most PSM of the complementary half after culture (Fig. 4p). In the *Msgn1*<sup>-/-</sup> PSM, a large, graded, expression domain was observed (Fig. 4q), and this pattern remained unchanged after culture (Fig. 4r) indicating that *Nrarp* expression didn't oscillate. Similarly, *Maml3* was broadly expressed in *Msgn1*<sup>-/-</sup> PSM, and the pattern remained unchanged after culture (Fig. 4w, x). These results demonstrate that neither *Msgn1*, nor Notch signaling, is required for *Nrarp* and *Maml3* activation, but *Msgn1* is necessary for their cyclic expression. In summary, the expression of *Dll1*, *Dll3*, *Notch1*, *Hes7* and *Lfng* was dramatically reduced in the posterior PSM by the absence of *Msgn1*, while *Nrarp* and *Maml3* expression was qualitatively different. The lack of oscillatory expression of cyclic Notch, Wnt, and Fgf target genes indicate that *Msgn1* plays a central and fundamental role in the segmentation clock.

### Genomic approaches to identify *Msgn1* target genes

To address the molecular mechanisms of *Msgn1* function in the clock and gradient, we sought to identify the target genes of *Msgn1* by genome-wide transcriptional profiling. Since early embryos provide extremely limiting amounts of tissue, ESC reagents were developed to exploit the ability of pluripotent ESC to self-renew indefinitely and to differentiate into mesoderm, including PSM, in vitro<sup>23</sup>. Recombinant ESC lines expressing a Doxycycline-inducible (Dox) FLAG epitope-tagged *Msgn1* (F-*Msgn1*) (Supplementary Fig. S2;<sup>32</sup>) were cultured in suspension for 2 days to initiate epiblast differentiation, and then induced with Dox to prematurely express *Msgn1*. Transcriptional profiles of embryoid bodies (EB) +/- F-*Msgn1* induction were assessed for differentially expressed genes. Examination of the cyclic Wnt (*Sp5* and *Axin2*) and Fgf (*Spry2* and *Dusp6*) pathway genes revealed that ectopic *Msgn1* expression had little effect on their expression (Supplementary Fig. S3). Conversely, multiple genes in the Notch pathway were induced >1.5-fold by *Msgn1*, including *Dll1*, *Dll3*, *Notch1*, and *Nrarp* (Fig. 5a, Supplementary Table 1). Differential *Lfng* expression was not statistically significant due to variable expression in both treated and untreated cells. Quantitative PCR (qPCR) analysis validated the microarray data for all Notch genes examined (Fig. 5b). Notably, *Maml3*, which is not represented on the Affymetrix MOE430 2.0 gene chips, was also upregulated. Thus *Msgn1* induced the expression of 6 different genes in the Notch signaling pathway.

The rapid activation of multiple Notch pathway genes suggests that *Msgn1* could regulate their transcription directly. To determine whether *Msgn1* binds to these loci, anti-Flag antibodies were used to immunoprecipitate chromatin bound to F-*Msgn1*, followed by sequencing (ChIP-seq) of F-*Msgn1*-associated DNA. Remarkably, multiple regions of the genome with significant enrichment in *Msgn1*-associated sequences were identified within,

or upstream of, genes in the Notch pathway. Large *Msgn1* peaks were found in conserved intronic regions of *Notch1*, *Notch2*, and *Maml3*, and in upstream regulatory regions of *Dll1*, *Dll3*, *Notch1* and *Lfng* (Fig. 6, 7). Small *Msgn1* peaks were also identified upstream of *Dll1* (Fig. 6a), *Nrarp* and *Sprouty2*, while none were associated with the *Hes7*, *Sp5*, *Axin2*, or *Dusp6* loci. Sequence analysis revealed the presence of at least one consensus E box motif (CANNTG) in each *Msgn1* peak (Fig. 6 and Supplementary Information). Since bHLH transcription factors bind to E boxes<sup>33</sup>, their presence is consistent with *Msgn1* activating Notch pathway genes by direct binding.

Interestingly, the two *Msgn1* peaks found in the *Lfng* locus precisely align with two previously described enhancers that drive *Lfng* expression in the PSM of transgenic embryos (Fig. 7a; <sup>31,34</sup>). Peaks were also identified in the *Dll1* and *Dll3* loci that are distinct from, but overlapping with, previously defined regulatory elements<sup>35,36</sup>. To test these putative enhancers for *Msgn1* responsiveness, peak sequences were cloned upstream of a minimal promoter driving the luciferase reporter and cotransfected with *Msgn1* or control expression vectors in NIH3T3 cells. *Msgn1* strongly transactivated the luciferase reporter in eight constructs (single peaks in *Dll1*, *Dll3*, *Notch2*, and *Maml3*, and 2 peaks in *Notch1*, and *Lfng* (Fig. 6b,d,f,h,j, Fig. 7c,d). Two small ChIP-seq peaks (*Dll1*-505 and -2313) immediately upstream of the *Dll1* transcriptional start site (TSS) were not found to be significantly different from control input DNA and thus were not scored as peaks. To verify that these sequences did not contain *Msgn1* responsive elements, we tested one (*Dll1*-2313) in reporter assays. *Dll1*-2313 did not respond to *Msgn1* expression despite the presence of E-boxes, thereby empirically validating the ChIP-seq analysis (Fig. 6b). The small peaks observed in *Nrarp* and *Sprouty2* upstream sequences are of similar size to *Dll1*-2313 and were therefore not examined further. These results demonstrate that the *Msgn1* ChIP-seq peaks examined are indeed cis-acting regulatory elements, and that *Msgn1* functions as a strong transcriptional activator of Notch pathway genes.

### ***Msgn1* directly activates the segmentation clock gene *Lfng***

We have shown that *Msgn1* can bind and activate regulatory enhancers of the cyclic genes *Dll1*, *Maml3*, and *Lfng*, and that *Msgn1* is required for the cyclic expression of *Dll1* and *Lfng* in vivo. These results strongly suggest that *Msgn1* is an important component of the segmentation clock. To address the mechanisms of *Msgn1* function in the clock, we focused on understanding the transcriptional regulation of *Lfng* since the regulatory elements are well-characterized in vivo<sup>31,34,37</sup>, and because *Lfng* is an important regulator of oscillating Notch activity<sup>37,38,39</sup>. *Lfng* transcription in the PSM is controlled by three separable, conserved elements termed blocks A, B, and C<sup>31</sup> found within a 2.3 kb region upstream of the TSS<sup>31,34,37</sup>. An RBP-J binding site (which confers Notch responsiveness) and two E-boxes identified within block A (Fringe Clock Element1<sup>34</sup>), regulate cyclic *Lfng* expression in the posterior PSM, while E and N boxes in block B regulate expression in the anterior PSM<sup>17,31,34,37</sup>. Our genomic ChIP-seq studies showed that *Msgn1* bound to both blocks A and B (Fig. 7a). Single gene ChIP-PCR assays in ESCs validated the ChIP-seq results, demonstrating that both blocks were highly enriched by F-*Msgn1* ChIP (Supplementary Fig. S4). Importantly, anti-*Msgn1* antibodies (Supplementary Fig. S5) detected endogenous *Msgn1* bound to *Lfng* regulatory blocks A and B in PSM extracts but not in control extracts of the head (Fig. 7b). Electrophoretic mobility shift assays (EMSA) confirmed that *Msgn1* protein indeed bound directly to E-box sequences found in the A and B block (Supplementary Fig. S6) but not to the closely-related N-boxes residing in block B. The results of the EMSA assays mirror the ChIP results, with *Msgn1* generally displaying greater binding affinity for block A than for block B in both assays. Together, these results conclusively demonstrate that *Lfng* is a direct target gene of *Msgn1*, and that *Msgn1* binds *Lfng* clock regulatory elements in vivo.

The binding of *Msgn1* to block A or to block B was sufficient to activate the expression of the luciferase reporter by 5–6-fold when either block was tested in isolation, however *Msgn1* alone did not strongly activate the reporter in the context of the longer 2.3 kb *Lfng* upstream region (Fig. 7c). This result argues that additional activators are required to generate a robust transcriptional response, and that negative factors also regulate *Lfng*. The 2.3 kb construct did not respond well to activated Notch (NICD) either, however the coexpression of *Msgn1* and NICD resulted in a synergistic 7–15-fold induction of luciferase activity (Fig. 7c, d). This *Msgn1*-Notch synergism was mediated by block A since synergism was not observed with reporter constructs that lacked block A (see constructs B, C, and BC), and was very strong (50–107 fold) when *Msgn1* and NICD were coexpressed with the block A enhancer alone (Fig. 7c, d). Negative regulators presumably bind to blocks B and C since the *Msgn1*-Notch synergism is adversely affected by the presence of these blocks. Together, the data demonstrate that *Msgn1* and the Notch signaling pathway regulate *Lfng* by binding directly to clock elements in block A to cooperatively activate transcription.

*Msgn1* activates the expression of multiple genes in the Notch pathway, including cyclic genes, however *Msgn1* is not expressed periodically. How then are some *Msgn1* target genes cyclically expressed, while others are not? In the case of the *Msgn1*-Notch target gene *Lfng*, oscillatory expression presumably arises from the dynamic activity of the Notch pathway. The *Hairy enhancer-of-split (Hes)* gene, *Hes7*, is a periodically expressed Notch target gene and bHLH transcription factor that is required for somitogenesis and cyclic gene expression<sup>40,41</sup>. *Hes7* has been proposed to function as the segmentation clock pacemaker as it operates in an autoinhibitory feedback loop and periodically represses *Lfng* transcription<sup>29</sup>. If *Msgn1* is a major driver of clock gene expression and *Hes7* is the pacemaker, then *Hes7* should repress the activating activity of *Msgn1* on *Lfng*. Indeed *Hes7* completely repressed the activation of the full-length 2.3 kb *Lfng* enhancer by *Msgn1* alone, or *Msgn1* and Notch together (Fig. 7d). Examination of *Hes7* activity on the isolated A or B blocks revealed that *Hes7* repressed the activation of the block B enhancer by *Msgn1* alone, but had no effect on the *Msgn1*-dependent activation of the block A cyclic enhancer. Since *Hes7*-binding N-boxes are only found in block B, these results argue that *Hes7* represses *Lfng* by binding to N-boxes. On the other hand, *Hes7* does repress the combined activity of *Msgn1* and Notch on the A block by 47% suggesting that at least some *Hes7* repressor activity is N-box independent. Nevertheless, *Msgn1* and Notch still function as powerful, synergistic activators of the *Lfng* block A clock enhancer, activating it 57-fold despite the presence of *Hes7*.

## Discussion

The original clock and wavefront model first proposed that the sequential and repetitive formation of somites arises from a cellular oscillator (the clock) periodically interacting with a wavefront of rapid cell change that moves progressively down the embryonic AP axis<sup>42</sup>. The discovery of oscillating genes in the Notch, Wnt3a and Fgf signaling pathways, and the demonstration that Wnt3a/Fgf signaling gradients define the traveling wavefront or determination front, suggests that Wnt3a functions in both the clock and the wavefront during somitogenesis. In this study, we have shown that Wnt3a controls the clock and the wavefront through the activation of the direct target gene *Msgn1* and that *Msgn1* plays a pivotal role in the segmentation clock by functioning to coordinate the Wnt and Notch pathways.

The expression of *Wnt3a* in the PS and tailbud<sup>13,21</sup> establishes a descending posterior-to-anterior nuclear gradient in the PSM of the transcriptional coactivator  $\beta$ -catenin<sup>18</sup>. This  $\beta$ -catenin gradient is reflected in the graded expression of some direct Wnt3a/ $\beta$ -catenin target genes such as *Axin2*<sup>13</sup>. *Axin2* appears to be universally responsive to Wnt/ $\beta$ -catenin

signaling since it is expressed at multiple sites of Wnt activity in the embryo and adult, as well as in Wnt/ $\beta$ -catenin-dependent tumors and cancer cell lines<sup>43,44,45,46</sup>. In contrast, *Msgn1* expression is restricted to the embryonic PSM and is less graded than *Axin2* during early somitogenesis stages, displaying a more defined border in the anterior PSM. The absence of *Msgn1* expression at other sites of Wnt activity argues that additional pathways are required for the activation of *Msgn1* in the PSM. This is supported by the demonstration that *Tbx6*, which is coexpressed with *Msgn1* in the PSM, cooperates with the Wnt3a/ $\beta$ -catenin pathway to directly regulate the *Msgn1* promoter (this work; <sup>24</sup>). The broad expression of *Msgn1* throughout the posterior PSM, collapses into a weak gradient in the absence of *Tbx6*, suggesting that a major function of *Tbx6* is to convert the “slope” of the Wnt3a gradient into a “step” of *Msgn1* expression that displays a defined anterior border.

The anterior *Msgn1* border lies immediately caudal to the segmental *Mesp2* stripe and therefore marks the position of the determination front. Recent genetic studies have shown that the Wnt3a/ $\beta$ -catenin gradient regulates somitogenesis, at least in part, by positioning the determination front in the anterior PSM<sup>8,18</sup>. Our present work demonstrates that these same genetic manipulations of Wnt signaling that alter the determination front position, also correspondingly alter the position of the anterior boundary of *Msgn1* expression. This boundary posteriorly regresses at the rate of one somite length during one period of somite formation<sup>47</sup>, indicating that the posterior-ward movement of the *Msgn1* expression domain parallels the regression of the wavefront. Importantly, activation of *Mesp2* and *Ripply2* does not occur in *Msgn1*<sup>-/-</sup> mutants (Fig. 3;<sup>20</sup>), suggesting that *Msgn1* is required for posterior PSM progenitors to transition to anterior PSM fates and establish a segmental pre-pattern. Taken together, the data strongly argue that the Wnt3a/ $\beta$ -catenin gradient controls determination front activity through *Msgn1*, and that the anterior border of *Msgn1* plays a key role in defining this activity.

Recent work has affirmed the essential role that the Notch pathway plays in the mammalian segmentation clock<sup>9</sup>. Wnt3a functions upstream of Notch to control cyclic gene expression in both the Wnt and Notch pathways, leading to the hypothesis that Wnt/ $\beta$ -catenin signaling drives the segmentation clock<sup>13</sup>. Studies of  $\beta$ -catenin mutants support this contention however the demonstration that *Lfng* continues to oscillate in the presence of a stabilized, non-cyclical form of  $\beta$ -catenin argues that  $\beta$ -catenin is not the clock pacemaker<sup>8,18</sup>. How then does the Wnt3a/ $\beta$ -catenin pathway regulate Notch signaling and the segmentation clock? One way is through the direct activation of *Dll1*<sup>12,48</sup>. We show here that Wnt3a, acting via *Msgn1*, has a much broader role in Notch regulation, activating almost the entire Notch signaling pathway including cyclic target genes. Thus *Msgn1* is a master regulator of the Notch pathway.

Although *Msgn1* is required for Notch target gene expression, the Wnt target genes *Sp5* and *Axin2* were upregulated in *Msgn1* mutants. This expression is similar to the enhanced expression previously reported<sup>20</sup> for another Wnt3a target gene *T/Brachyury*<sup>49</sup>, suggesting that *Msgn1* directly, or indirectly, represses some Wnt targets. The divergent response of Wnt and Notch targets suggest that *Msgn1* functions to coordinate these pathways in the segmentation clock. Despite our proposal that it plays a central role in the clock, *Msgn1* is unlikely to function as the pacemaker since it is not expressed periodically. Our demonstration that *Hes7* blocks the synergistic *Msgn1*-Notch activation of *Lfng* is consistent with previous suggestions that *Hes7* is the pacemaker<sup>29</sup>. We suggest that cyclic gene expression in the Notch pathway requires two primary regulatory components: an activator, arising from the combined activity of *Msgn1* and the Notch signaling pathway, and a short-lived periodic repressor, *Hes7*, which functions in an autoinhibitory feedback loop to periodically repress *Hes7* and *Lfng* (Fig. 8). Although it is well known that the Fgf pathway

is also required for cyclic gene expression and for the proper expression of *Msgn1*<sup>10</sup>, the precise mechanisms remain unclear.

Interactions between the Notch and Wnt pathways are known to regulate the maintenance of stem cells, including hematopoietic and gastrointestinal stem cells<sup>50,51,52</sup>. This raises the intriguing possibility that a similar relationship between the Wnt and Notch pathways could maintain mesodermal stem cells in the segmenting embryo. *Msgn1* regulates the maturation of these mesodermal progenitors since they accumulate as an undifferentiated mass in the tailbud of *Msgn1*<sup>-/-</sup> embryos<sup>20</sup> and display impaired anterior-ward migration and epithelial-mesenchymal transitions (EMT). Since *Wnt3a* regulates the same processes, then it is possible that *Wnt3a* regulates mesodermal stem cell homeostasis, migration, EMT, and positional information through *Msgn1*. The identification of the interacting proteins, and the genomic targets, of *Msgn1* will greatly assist in our understanding of how Wnt signals regulate such numerous and diverse processes.

## Materials and Methods

### Mice

*Ctnnb1*<sup>tm2Kem</sup> mice were purchased from the Jackson Labs. The *Wnt3a*<sup>21</sup>, *Mesogenin1*<sup>20</sup>, *Ctnnb1*<sup>lox(ex3)</sup><sup>53</sup>, *Tbx6*<sup>25</sup> and *T-cre* mice<sup>54</sup> were obtained from the originating labs. Transgenic mice were generated in the Transgenic Core Facility, NCI-Frederick, by pronuclear injection following standard procedures. All animal experiments were performed in accordance with the guidelines established by the NCI-Frederick Animal Care and Use Committee.

### Whole-mount in situ hybridization

Single and double whole-mount in situ hybridization (WISH) and section ISH were performed as described<sup>15</sup>. Unless indicated otherwise, at least 4 mutant embryos were examined for each probe, and all yielded similar results.

### ES cell culture, Maintenance and Differentiation

Serum independent GFP-Bry ES cells were maintained and differentiated into mesoderm as described<sup>23</sup>. Recombinant *Wnt3a* protein (R&D Systems) was added to embryoid bodies on D2 of differentiation and cells were harvested for RNA extraction 48 hours later.

The *Msgn1* ORF with N-terminal 1× or 3× FLAG tags was cloned into p2lox targeting vector and site-specific recombination was accomplished by inducing A2lox.cre ESCs<sup>32</sup> with Doxycycline (Dox) 24 hours prior to electroporation with the P2lox-FLAG-*Msgn1* vector. For EB differentiation, ESC were plated on 10cm Petri dishes at a density of 2.5 million cells per plate in 15ml of DMEM, 10% FBS, NEAA, Pen/Strep, 2-Mercaptoethanol and 50ug/ml ascorbic acid (Sigma). After 2 days of differentiation, EBs were then transferred to 6 well ultra low attachment dishes (Corning) and expression of FLAG-*Msgn1* was induced using 1ug/ml Dox. Samples were collected at 12h interval up to 48h. The same EB differentiation protocols were used for transcriptional profiling and ChIP-seq assays.

### Gene expression profiling

Gene expression profiling on microdissected node and primitive streak regions of E7.75-E8 wildtype and *Wnt3a*<sup>-/-</sup> embryos was performed as described<sup>8</sup>. For ESC expression profiling, total RNA was isolated using RNeasy mini kit (Qiagen) from EBs treated with and without doxycycline at 12h, 24h and 48h time intervals according to manufacturer's instructions. Protocols for synthesis of cDNA and cRNA were performed using the Affymetrix Genechip 3' IVT Express kit (Affymetrix, Santa Clara, CA) according to manufacturer's



recommendations. Statistical analysis was performed on probe-intensity level data (CEL files) using Genespring GX10 (Agilent) and BRB ArrayTools v.3.2 software. Initial filtering and preprocessing, including background correction, quantile normalization and summarization, was performed using the robust multi-array analysis (RMA) algorithm. Statistical analyses were performed using an unpaired T-test at  $p < 0.05$  on genes displaying a fold change of 1.5 or greater. The mean-normalized intensity values ( $\log_2$  values) and standard deviation for each gene were calculated and plotted.

### **Antibody Production, Western Blot Analysis and Immunocytochemistry**

Polyclonal mouse antibodies against Msn1 protein were made by A&G Precision antibody (Columbia, MD) using a cocktail of peptides CWKSRARPLELVQESP, CDLLNSSGREPRQSV, CSHEAAGLVELDYS conjugated to KLH antigen.

### **Chromatin immunoprecipitation Assays**

ChIP of EBs: 36 hours after Dox induction, EBs were fixed in 1% formaldehyde solution for 15 min and quenched with 0.125M Glycine. Cells were lysed with lysis buffer and chromatin was sheared to an average length of 300-500bp as described<sup>55</sup>. Protein DNA complexes were immunoprecipitated using anti-FlagM5 antibody or corresponding isotype. Crosslinks were reversed and DNA was extracted with phenol:chloroform and purified by ethanol precipitation.

The Chromatin immunoprecipitation-sequencing (ChIP-Seq) approach was performed by Genpathway (San Diego, California)<sup>56</sup>. Briefly EBs were fixed and quenched as described above, and flash frozen. The nuclei were extracted, sonicated and precleared with Staph A cells (Pansorbin, Calbiochem, San Diego, CA) before incubation with anti-Flag M2 antibody (Sigma). Samples were incubated with prepared Staph A cells to extract antibody-chromatin complexes, followed by washing and elution. Precipitated DNA fragments were released and purified. ChIP DNA fragments associated with FLAG-Msn1 were amplified using the Illumina ChIP-Seq DNA sample prep kit (Illumina, San Diego, CA). DNA libraries were sequenced on a Genome Analyzer II by Illumina Sequencing Services. 35-nt sequence reads were mapped to the genome using the Eland algorithm. The 35bp sequences were extended in silico at the 3' end up to 110bp, which is the average DNA fragment length after shearing. The resulting histograms were stored in BAR (Binary Analysis Results) files. For each BAR file, intervals were calculated and compiled into BED files (Browser Extensible Data) for viewing in the UCSC genome browser. Enriched intervals, referred to as peak values, were determined by applying a threshold p-value cutoff of  $10e-5$  and a false discovery rate (FDR) of 2.35%. BAR files were uploaded to the Integrated Genome Browser (IGB-Affymetrix) for extensive analysis.

ChIP of embryo tissues: About 60 PSMs and 25 heads from E9.5 stage embryos were collected and fixed overnight in 4% PFA at 4°C and dehydrated in methanol series<sup>57</sup>. On the day of the CHIP assay, PSM and head tissues were rehydrated, cross-linked with 1% formaldehyde for 15min at room temperature and quenched with 0.125M glycine. Tissues were washed 2x with ice-cold PBS, resuspended in lysis buffer LB1<sup>55</sup> and disrupted by passing through 26 3/8 gauge needle. Pellets in lysis buffer LB3 were sonicated using Branson Sonifer450 and lysates were pre-cleared for 15min at 4°C with 20ul proteinG dynal beads (Invitrogen) pre-blocked with 0.5% BSA in PBS and 1mg/ml sonicated salmon sperm DNA (Ambion). Equal amounts of lysates were immunoprecipitated with anti-Msn1 ascites or control ascites (Clone NS-1; Sigma).

### Half-embryo explant cultures

Half-embryo explant cultures were done as described<sup>8</sup>. PSM explants of wild type and *Msgn1*<sup>-/-</sup> embryos were dissected at E8.25-E8.5 and manually bisected along the midline. The left half of the embryo was immediately fixed in 4% PFA, while the right half was cultured at 37C for 60 or 90 minutes in DMEM with 10% FBS supplemented with 10ng/ml bFGF (R and D Systems) before fixation.

### Expression constructs, transfections, cell culture and luciferase reporter assays

Reporter constructs of 1 kb *Msgn1* promoter and mutant version of 3 TCF/LEF binding sites were generated in pGL4.10(luc2) vector (Promega). For generating transgenic mice, the hsp68 minimal promoter was replaced with the wildtype and TCF/LEF mutated 1kb *Msgn1* promoter followed by lacZ and SV40polyA signal in pASShsp68-lacZ-pA vector. The luciferase reporter construct containing the 2.3kb *Lunatic-fringe* cyclic enhancer<sup>31</sup>, *Lfng* enhancer deletion constructs, and positively identified CHIP seq peaks were generated in the pGL4.23 [*minp-luc2*] vector (Promega). HEK293T cells or NIH 3T3 cells were seeded at  $0.25 \times 10^5$  cells per well in 24 well plates and cultured for 18 hours. A total of 500ng of DNA containing the reporter plasmids (200ng) and empty luciferase vectors were co-transfected with or without expression vectors pSG5-T-VP16 (50ng), pcDNA-Tbx6-VP16 (50ng),  $\Delta N$ - $\beta$ catenin-myc (50ng), pCS2-Myc-Msgn1 (100ng), CMV-3xFlag-Mesp2 (100ng), and pCS2-NICD-Venus (50ng), CMV-3xFlag-Hes7 (100ng) using Lipofectamine 2000 (Invitrogen). Equivalent amounts of DNA were achieved with pcDNA3 or pCS2 vector. Cells were lysed 40 hours after transfection and luciferase activity was measured using the Dual Luciferase Assay Kit (Promega) as per manufacturers recommendations. In each condition, 5ng of pGL4.74 [hRluc/TK] Vector (Promega) was used as an internal control to normalize for transfection efficiency. Fold change was calculated as a ratio of the luciferase vector containing *Msgn1* or *Lfng* regulatory elements relative to empty luciferase vector for identical experimental conditions, normalized to a control condition minus expression vectors. The reported values are from one experiment but are representative of at least three independent experiments.

### Electrophoretic mobility shift assay

Lef1 and Myc-Msgn1 proteins were made using the TNT Reticulocyte Lysate System (Promega) in vitro. Double stranded DNA oligonucleotides were end labeled with DIG-ddUTP and protein-DNA complexes were analyzed using the DIG Gel Shift Assay Kit (Roche) according to manufacturer's instructions.

### Reverse Transcription and qPCR

1ug of RNA was DnaseI treated and first-strand cDNA was synthesized using oligo dT and superscript III reverse transcriptase (Invitrogen) or iScript cDNA synthesis kit (Roche) according to manufacturers instructions. qPCR analysis was used to quantitate cDNAs using CFX96 Real-Time PCR Detection System (Bio-Rad) and Fast Start Universal SYBR Green Master (Roche). For the qPCR results shown in Fig.1h, Taqman gene expression assays were performed (Mm00490407\_S1) using Taqman universal PCR Master Mix (Applied Biosystems) according to manufacturer's recommendations. *Gapdh* expression was used to normalize *Msgn1* expression values. The specificity of all primers was monitored by electrophoresis of the amplicons on agarose gels. The mean expression values obtained for each gene were normalized to GAPDH ( $\Delta\Delta C(t)$  method) and to the expression in undifferentiated ES cells. For normalization of CHIP-qPCR analysis, first percent input method was used to calculate from the obtained Ct values and was further normalized to the values obtained in the control ascites to obtain the fold change values. All CHIP and qPCR experiments were done in triplicates.

See Supplementary Table S2 for oligonucleotide sequences used in EMSA and qPCR assays.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


We thank Y. Saga, B. Herrmann, and R. Kageyama for providing reagents. We are grateful to S. Mackem, A. Perantoni, M. Lewandoski, M. Anderson, N. Adler, and M. Kennedy for providing comments on versions of this manuscript. We are particularly indebted to J. Greear and R. Wolfe (SAIC-Frederick) for excellent animal husbandry. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

## References

1. Dequeant ML, et al. A complex oscillating network of signaling genes underlies the mouse segmentation clock. *Science*. 2006; 314:1595–1598. [PubMed: 17095659]
2. Dequeant ML, Pourquie O. Segmental patterning of the vertebrate embryonic axis. *Nat Rev Genet*. 2008; 9:370–382. [PubMed: 18414404]
3. Aulehla A, Johnson RL. Dynamic expression of lunatic fringe suggests a link between notch signaling and an autonomous cellular oscillator driving somite segmentation. *Dev Biol*. 1999; 207:49–61. [PubMed: 10049564]
4. Forsberg H, Crozet F, Brown NA. Waves of mouse Lunatic fringe expression, in four-hour cycles at two-hour intervals, precede somite boundary formation. *Curr Biol*. 1998; 8:1027–1030. [PubMed: 9740806]
5. McGrew MJ, Dale JK, Fraboulet S, Pourquie O. The lunatic fringe gene is a target of the molecular clock linked to somite segmentation in avian embryos. *Curr Biol*. 1998; 8:979–982. [PubMed: 9742402]
6. Palmeirim I, Henrique D, Ish-Horowicz D, Pourquie O. Avian hairy gene expression identifies a molecular clock linked to vertebrate segmentation and somitogenesis. *Cell*. 1997; 91:639–648. [PubMed: 9393857]
7. Aulehla A, et al. Wnt3a plays a major role in the segmentation clock controlling somitogenesis. *Dev Cell*. 2003; 4:395–406. [PubMed: 12636920]
8. Dunty WC Jr. et al. Wnt3a/beta-catenin signaling controls posterior body development by coordinating mesoderm formation and segmentation. *Development*. 2008; 135:85–94. [PubMed: 18045842]
9. Ferjentsik Z, et al. Notch is a critical component of the mouse somitogenesis oscillator and is essential for the formation of the somites. *PLoS Genet*. 2009; 5:e1000662. [PubMed: 19779553]
10. Wahl MB, Deng C, Lewandoski M, Pourquie O. FGF signaling acts upstream of the NOTCH and WNT signaling pathways to control segmentation clock oscillations in mouse somitogenesis. *Development*. 2007; 134:4033–4041. [PubMed: 17965051]
11. Nakaya MA, et al. Wnt3a links left-right determination with segmentation and anteroposterior axis elongation. *Development*. 2005; 132:5425–5436. [PubMed: 16291790]
12. Galceran J, Sustmann C, Hsu SC, Folberth S, Grosschedl R. LEF1-mediated regulation of Delta-like1 links Wnt and Notch signaling in somitogenesis. *Genes Dev*. 2004; 18:2718–2723. [PubMed: 15545629]
13. Aulehla A, et al. Wnt3a plays a major role in the segmentation clock controlling somitogenesis. *Dev. Cell*. 2003; 4:395–406. [PubMed: 12636920]
14. Dubrulle J, McGrew MJ, Pourquie O. FGF signaling controls somite boundary position and regulates segmentation clock control of spatiotemporal Hox gene activation. *Cell*. 2001; 106:219–232. [PubMed: 11511349]


15. Biris KK, Dunty WC Jr, Yamaguchi TP. Mouse Ripply2 is downstream of Wnt3a and is dynamically expressed during somitogenesis. *Dev Dyn*. 2007; 236:3167–3172. [PubMed: 17937396]
16. Morimoto M, et al. The negative regulation of Mesp2 by mouse Ripply2 is required to establish the rostral-caudal patterning within a somite. *Development*. 2007; 134:1561–1569. [PubMed: 17360776]
17. Morimoto M, Takahashi Y, Endo M, Saga Y. The Mesp2 transcription factor establishes segmental borders by suppressing Notch activity. *Nature*. 2005; 435:354–359. [PubMed: 15902259]
18. Aulehla A, et al. A beta-catenin gradient links the clock and wavefront systems in mouse embryo segmentation. *Nat Cell Biol*. 2008; 10:186–193. [PubMed: 18157121]
19. Stadeli R, Hoffmanns R, Basler K. Transcription under the control of nuclear Arm/beta-catenin. *Curr Biol*. 2006; 16:R378–385. [PubMed: 16713950]
20. Yoon JK, Wold B. The bHLH regulator pMesogenin1 is required for maturation and segmentation of paraxial mesoderm. *Genes Dev*. 2000; 14:3204–3214. [PubMed: 11124811]
21. Takada S, et al. Wnt-3a regulates somite and tailbud formation in the mouse embryo. *Genes Dev*. 1994; 8:174–189. [PubMed: 8299937]
22. Yoon JK, Moon RT, Wold B. The bHLH class protein pMesogenin1 can specify paraxial mesoderm phenotypes. *Dev Biol*. 2000; 222:376–391. [PubMed: 10837126]
23. Gadue P, Huber TL, Paddison PJ, Keller GM. Wnt and TGF-beta signaling are required for the induction of an in vitro model of primitive streak formation using embryonic stem cells. *Proc Natl Acad Sci U S A*. 2006; 103:16806–16811. [PubMed: 17077151]
24. Wittler L, et al. Expression of Msn1 in the presomitic mesoderm is controlled by synergism of WNT signalling and Tbx6. *EMBO Rep*. 2007; 8:784–789. [PubMed: 17668009]
25. Chapman DL, Papaioannou VE. Three neural tubes in mouse embryos with mutations in the T-box gene Tbx6. *Nature*. 1998; 391:695–697. [PubMed: 9490412]
26. Wright D, et al. Cyclic Nrarp mRNA expression is regulated by the somitic oscillator but Nrarp protein levels do not oscillate. *Dev Dyn*. 2009; 238:3043–3055. [PubMed: 19882724]
27. Sewell W, et al. Cyclical expression of the Notch/Wnt regulator Nrarp requires modulation by Dll3 in somitogenesis. *Dev Biol*. 2009; 329:400–409. [PubMed: 19268448]
28. Williams DA, et al. Identification of oscillatory genes in somitogenesis from functional genomic analysis of a human mesenchymal stem cell model. *Dev Biol*. 2007; 305:172–186. [PubMed: 17362910]
29. Bessho Y, Hirata H, Masamizu Y, Kageyama R. Periodic repression by the bHLH factor Hes7 is an essential mechanism for the somite segmentation clock. *Genes Dev*. 2003; 17:1451, 1456. [PubMed: 12783854]
30. Barrantes IB, et al. Interaction between Notch signalling and Lunatic fringe during somite boundary formation in the mouse. *Curr Biol*. 1999; 9:470–480. [PubMed: 10330372]
31. Morales AV, Yasuda Y, Ish-Horowitz D. Periodic Lunatic fringe expression is controlled during segmentation by a cyclic transcriptional enhancer responsive to notch signaling. *Dev Cell*. 2002; 3:63–74. [PubMed: 12110168]
32. Iacovino M, et al. A conserved role for Hox paralog group 4 in regulation of hematopoietic progenitors. *Stem Cells Dev*. 2009; 18:783–792. [PubMed: 18808325]
33. Murre C, et al. Structure and function of helix-loop-helix proteins. *Biochim Biophys Acta*. 1994; 1218:129–135. [PubMed: 8018712]
34. Cole SE, Levorse JM, Tilghman SM, Vogt TF. Clock regulatory elements control cyclic expression of Lunatic fringe during somitogenesis. *Dev Cell*. 2002; 3:75–84. [PubMed: 12110169]
35. Beckers J, et al. Distinct regulatory elements direct delta1 expression in the nervous system and paraxial mesoderm of transgenic mice. *Mech Dev*. 2000; 95:23–34. [PubMed: 10906447]
36. Henke RM, Meredith DM, Borromeo MD, Savage TK, Johnson JE. Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube. *Dev Biol*. 2009; 328:529–540. [PubMed: 19389376]
37. Shifley ET, et al. Oscillatory lunatic fringe activity is crucial for segmentation of the anterior but not posterior skeleton. *Development*. 2008; 135:899–908. [PubMed: 18234727]

38. Dale JK, et al. Periodic notch inhibition by lunatic fringe underlies the chick segmentation clock. *Nature*. 2003; 421:275–278. [PubMed: 12529645]
39. Evrard YA, Lun Y, Aulehla A, Gan L, Johnson RL. lunatic fringe is an essential mediator of somite segmentation and patterning. *Nature*. 1998; 394:377–381. [PubMed: 9690473]
40. Bessho Y, Miyoshi G, Sakata R, Kageyama R. Hes7: a bHLH-type repressor gene regulated by Notch and expressed in the presomitic mesoderm. *Genes Cells*. 2001; 6:175–185. [PubMed: 11260262]
41. Bessho Y, et al. Dynamic expression and essential functions of Hes7 in somite segmentation. *Genes Dev*. 2001; 15:2642–2647. [PubMed: 11641270]
42. Cooke J, Zeeman EC. A clock and wavefront model for control of the number of repeated structures during animal morphogenesis. *J Theor Biol*. 1976; 58:455–476. [PubMed: 940335]
43. Jho EH, et al. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. *Mol Cell Biol*. 2002; 22:1172–1183. [PubMed: 11809808]
44. Leung JY, et al. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. *J Biol Chem*. 2002; 277:21657–21665. [PubMed: 11940574]
45. Lustig B, et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. *Mol Cell Biol*. 2002; 22:1184–1193. [PubMed: 11809809]
46. Sansom OJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. *Genes Dev*. 2004; 18:1385–1390. [PubMed: 15198980]
47. Gomez C, et al. Control of segment number in vertebrate embryos. *Nature*. 2008; 454:335–339. [PubMed: 18563087]
48. Hofmann M, et al. WNT signaling, in synergy with T/TBX6, controls Notch signaling by regulating Dll1 expression in the presomitic mesoderm of mouse embryos. *Genes Dev*. 2004; 18:2712–2717. [PubMed: 15545628]
49. Yamaguchi TP, Takada S, Yoshikawa Y, Wu N, McMahon AP. T (Brachyury) is a direct target of Wnt3a during paraxial mesoderm specification. *Genes Dev*. 1999; 13:3185–3190. [PubMed: 10617567]
50. Duncan AW, et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. *Nat Immunol*. 2005; 6:314–322. [PubMed: 15665828]
51. Fre S, et al. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. *Proc Natl Acad Sci U S A*. 2009; 106:6309–6314. [PubMed: 19251639]
52. van Es JH, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. *Nature*. 2005; 435:959–963. [PubMed: 15959515]
53. Harada N, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. *Embo J*. 1999; 18:5931–5942. [PubMed: 10545105]
54. Perantoni AO, et al. Inactivation of FGF8 in early mesoderm reveals an essential role in kidney development. *Development*. 2005; 132:3859–3871. [PubMed: 16049111]
55. Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation and microarray-based analysis of protein location. *Nat Protoc*. 2006; 1:729–748. [PubMed: 17406303]
56. Stahl HF, et al. miR-155 inhibition sensitizes CD4+ Th cells for TREG mediated suppression. *PLoS One*. 2009; 4:e7158. [PubMed: 19777054]
57. Pilon N, et al. Cdx4 is a direct target of the canonical Wnt pathway. *Dev Biol*. 2006; 289:55–63. [PubMed: 16309666]
58. Frazer KA, Pachter L, Poliakov A, Rubin EM, Dubchak I. VISTA: computational tools for comparative genomics. *Nucleic Acids Res*. 2004; 32:W273–279. [PubMed: 15215394]




**Figure 1. *Msgn1* lies downstream of *Wnt3a*/β-catenin signaling**

**a)** Hierarchical clustering was used to visualize differences in *Msgn1* expression between E7.75-8 wildtype and *Wnt3a*<sup>-/-</sup> embryos ( $p < 0.05$ ) as detected by Affymetrix microarrays. Each column represents a pool of three stage-matched embryos. Upregulated (red) and downregulated (blue) gene expression is shown, with the magnitude of change reflected by the color intensity. Color scale bar represents log intensity values. **(b, c)** WISH analysis of *Wnt3a* expression in the PS ectoderm **(b)**, and *Msgn1* expression in the adjacent PS mesoderm **(c)**, of E7.5 wildtype embryos. **(d-g)** WISH analysis of *Msgn1* expression in the posterior PSM of *Wnt3a*<sup>+/-</sup> **(d)**, *Wnt3a*<sup>-/-</sup> **(e)**, *T-Cre; Ctnnb1*<sup>LOF</sup> **(f)**, *T-Cre; Ctnnb1*<sup>GOF</sup> **(g)** embryos at E8.5. Note that *Msgn1* expression in the posterior PSM defines the oscillatory field. **(h)** qPCR analysis of *Msgn1* expression, normalized to *Gapdh* levels, in GFP-Bry ESC treated with recombinant *Wnt3a* in serum-free conditions. Error bars represent standard deviation of 3 samples. Abbr.: LOF, loss of function; GOF, gain of function. Scale bar = 100 μm.




**Figure 2. *Msn1* is directly activated by the Wnt/ $\beta$ -catenin pathway and *Tbx6***  
**(a)** VISTA “peaks and valleys” plot<sup>58</sup> illustrating a comparative analysis of the mouse and human *Msn1* loci (blue) including 1 kb of the upstream regulatory region (pink). The percent of conservation (y axis) between the two organisms is plotted against the coordinates of the mouse sequence (x axis). The pink regions are conserved non-coding regions, and the blue region is the conserved *Msn1* exon. The position and orientation of conserved consensus Tcf/LeF (red bars) and Tbx6 (green bar) binding sites identified in the promoter are displayed below the VISTA plot. Asterisks indicate nucleotides mutated for EMSA and transgenic reporter assays. **(b)** EMSA assay demonstrating the specific binding of Lef1 protein to Tcf/LeF BS probes but not to probes carrying mutated Tcf/LeF sites (asterisks). Lef1 binding to wildtype probes is competed by the addition of 125 times excess unlabeled probe. **(c)** Luciferase reporter assays for 1kb of the mouse *Msn1* promoter. Transfection of 293 cells with  $\Delta$ N- $\beta$ -catenin, or *Tbx6*-VP16 alone moderately activated the wild-type 1kb *Msn1* promoter, whereas cotransfection of both  $\Delta$ N- $\beta$ -catenin and *Tbx6*-VP16 resulted in a 7-fold activation. Coexpression of T-VP16 with  $\Delta$ N- $\beta$ -catenin did not result in a similar effect. Point mutations in all three Tcf/LeF BS abolished the activation of the luciferase reporter by *Tbx6*-VP16 and/or  $\Delta$ N- $\beta$ -catenin. **(d)** Representative transient transgenic embryos expressing the 1kb wildtype *Msn1* promoter-*lacZ* reporter (left) or a mutant version carrying mutations in all three Tcf/LeF BS (right). The fraction (bottom left corner) represents the number of embryos displaying the demonstrated pattern/total number of  $\beta$ gal positive transgenic founders. **(e,f)** 2 color WISH of *Msn1* (purple) and *Tbx6* (orange) coexpression in E9 PSM, **(e)** and **(f)** are dorsal and lateral views, respectively. *Tbx6* expression extends beyond the anterior border of *Msn1* expression. **(g,h)** Dorsal-posterior views of *Msn1* mRNA in E8.5 wildtype littermate controls **(g)** and *Tbx6*<sup>-/-</sup> **(h)** embryos, oriented with posterior pointing down. Abbr.: BS, binding site; LOF, loss of function; GOF, gain of function; PS, primitive streak; PSM, posterior presomitic mesoderm. Scale bar = 100  $\mu$ m.



**Figure 3. Segment boundary determination genes are not expressed in *Msgn1* mutants**  
 Two-color WISH expression analysis of E8.5 wildtype (a,c), and *Msgn1*<sup>-/-</sup> (b,d) embryos for the expression of *Fgf8* (orange) and *Ripply2* (purple) (a,b) and *Uncx4.1* (orange) and *Mesp2* (purple) (c,d). All views are lateral, and embryos are oriented with anterior to the left. Scale bar = 100  $\mu$ m.







#### Figure 4. Segmentation clock gene expression in *Msgn1*<sup>-/-</sup> mutants

WISH analysis of *Sp5* (a-f), *Sprouty2* (g-l), *Dll1* (m,n), *Dll3* (s,t), *Notch1* (y,z), *Hes7* (a',b'), *Lfng* (c',d'), *Nrarp* (e',f',o-r), and *Maml3* (u-x) expression in wildtype (a,c,d,g,i,j,m,o,p,s,u,v,y,a',c',e') or *Msgn1*<sup>-/-</sup> (b,e,f,h,k,l,n,q,r,t,w,x,z,b',d',f') embryos at E8.5. The cyclic Wnt target genes *Sp5* (n=4; a, b) and *Axin2* (n=6, not shown) were upregulated in the *Msgn1*<sup>-/-</sup> PSM, while the overall expression levels of the oscillating Fgf pathway genes *Sprouty2* (n=5; g, h) and *Dusp6* (n=4, not shown)<sup>1</sup>, were maintained in *Msgn1*<sup>-/-</sup> embryos at levels similar to that observed in control embryos. In contrast, *Dll1* (n=5; m,n), *Dll3* (n=5; s,t), *Notch1* (n=5; y,z), *Hes7* (n=5; a',b'), and *Lfng* (n=8; c',d') were significantly downregulated in the posterior PSM. Weak stripes of expression were frequently detected in the anterior PSM (arrows, c',d') of E8.5 mutants that were not observed at E9.5<sup>20</sup>. *Nrarp* (n=9; e',f') and *Maml3* (n=11; not shown) were strongly expressed in the posterior PSM. *Nrarp* was not expressed in stripes in *Msgn1*<sup>-/-</sup> embryos as it is in wildtype littermates, and expression was graded, more closely resembling Wnt target gene expression than Notch target genes (compare Fig. 4f' with 4b and d'). (c-f,i-l,o-r,u-x) Lateral views of half-embryo explants analyzed by WISH. Using the explanted PSM “fix and culture” method, gene expression was assessed in a fixed, reference PSM explanted from one half of a wildtype or *Msgn1*<sup>-/-</sup> embryo (t=0), and compared to its expression in the complementary half after it had been cultured for roughly a half cycle of cyclic gene expression (60-90 minutes). The expression patterns of *Sp5* (n=2; c, d) *Axin2* (n=2, not shown), *Sprouty2* (n=2; i, j), *Nrarp* (n=5, o,p), and *Maml3* (n=2; u,v) differed between fixed (t=0) and cultured (t=60-90') wildtype control explants as expected, indicative of dynamic

oscillating expression, but did not change significantly between fixed (t=0) and cultured (t=60-90') *Msgn1*<sup>-/-</sup> halves. Scale bar = 100 μm.




**Figure 5. Expression of *Msgn1* in differentiating ESC rapidly induces Notch signaling genes**  
**(a)** Microarray analysis of gene expression in F-*Msgn1* EBs in the absence (blue) and presence of Dox (red) over a 48 hour timecourse. log<sub>2</sub> ratios of the normalized expression levels of *Dll1*, *Dll3*, *Notch1*, *Lfng*, *Nrarp* and the housekeeping control *Gapdh* are presented. *Lfng* expression was variable in Dox treated and untreated cells, presumably reflecting the dynamic expression of a cyclic gene, but was generally elevated by F-*Msgn1* expression. Error bars indicate standard deviation of 3 biological replicates. **(b)** qPCR analysis of Notch pathway gene expression in F-*Msgn1* ESC and EBs validates the microarray results shown in **(a)**. Here error bars indicate standard deviation of 3 replicates. Abbreviations: ES, embryonic stem cells; Dox, Doxycycline.



**Figure 6. F-Msgn1 binds directly to regulatory elements to transactivate multiple Notch pathway genes**

(a,c,e,g,i) F-Msgn1 immunoprecipitation in differentiating EBs enriches for chromatin at regulatory regions of Notch signaling genes. The y-axis denotes the peak values, and peaks are numbered according to their position of the peak midpoint relative to the transcriptional start site. Gene loci are depicted at the bottom of each panel and the arrowheads indicate orientation. Pink arrows indicate the ChIP-seq enhancer elements tested in the luciferase reporter assays depicted in the column on the right. (b,d,f,h,j) Sequences identified by F-Msgn1 ChIP-seq were tested for functional activity in *luciferase* reporter assays in NIH3T3 cells. Putative enhancer constructs are schematized at the top with red boxes indicating identified E-box consensus sequences. Luciferase reporter results are depicted in the graphs as fold changes. With the exception of *Dll1-2313*, all reporter constructs were strongly activated by Msgn1 expression. *Dll1-2313* represents a weak F-Msgn1 ChIP-seq peak that falls below, and therefore empirically validates, the applied p-value threshold of  $10e-5$ .



**Figure 7. *Msn1* binds directly to clock enhancers in ESCs and in vivo and synergizes with Notch to activate *Lfng***

(a) F-Msgn1 ChIP-seq peaks map to demonstrated clock enhancers in blocks A and B in the 5' regulatory region of *Lfng* in differentiating EBs. Blocks A, B (and C) represent regions of sequence homology conserved between mouse and human<sup>31,34</sup>. (b) ChIP-qPCR analysis performed on PSMs or head tissue dissected from wildtype embryos demonstrate that endogenous Msn1 binds strongly to Blocks A and B of the *Lfng* enhancer in the PSM, relative to the head, and not to control regions in intron 1. Y axis represents fold change. Abbreviations: C, control ascites fluid; aM, anti-Msgn1. (c) *Lfng-luciferase* reporter constructs containing up to 2.3kb of the *Lfng* enhancer/promoter are depicted on the left. Circles depict Rbpjk binding sites while triangles represent E-boxes. The luciferase activity for each construct, cotransfected with control (purple), Msn1 (green), and/or activated Notch (NICD, blue) expression constructs in 3T3 cells is expressed as a fold change on the right. Msn1 plus NICD (red) synergistically activate the full length (FL) 2.3kb *Lfng* construct 7.4 fold, and the block A construct 49.7 fold. The A block is the only element capable of negotiating synergistic interactions between Msn1 and NICD. (d) The cyclic transcriptional repressor Hes7 (orange) completely blocks the Msn1/NICD synergism on the FL *Lfng* enhancer construct and requires the B block for maximal inhibitory activity. The combined activities of Hes7 with NICD (yellow), Hes7 and Msn1 (pink), and Hes7 with Msn1+NICD (gray) are illustrated.

